mRNA Covid Vaccines Show Potential in Battling Cancer

Strategic Insights -

Scientists have discovered that mRNA Covid vaccines, developed to combat Covid-19, may have an unexpected benefit in extending the lifespan of cancer patients. The groundbreaking research, published in the journal Nature, analyzed medical records of over 1,000 individuals suffering from lung cancer or melanoma and found that patients with a specific form of lung cancer who received an mRNA coronavirus jab experienced a "near doubling in survival time" from 21 months to 37 months. The study's findings suggest that mRNA vaccines have an "apparent life-extending effect" by "revving up the body's immune system" and "programming a response to kill the cancer".

Key Takeaways:

  • The mRNA Covid vaccine was found to have a "near doubling in survival time" for patients with a specific form of lung cancer, increasing their lifespan from 21 months to 37 months.
  • The study examined medical records of over 1,000 individuals suffering from lung cancer or melanoma and found a significant survival benefit for vaccinated patients.
  • The survival benefit was seen specifically in patients with metastatic melanoma and those whose tumours had traits hinting that they were unlikely to respond to checkpoint inhibitors.
  • The mRNA vaccine was found to have an immune-boosting effect, activating the immune system throughout the body and inside the tumour.
  • Researchers noted that the survival benefit was not seen in patients who received vaccines that do not use mRNA technology, such as those for influenza and pneumonia, or in people who received a different type of cancer therapy.
  • The study's co-author, Adam Grippin, a radiation oncologist at MD Anderson Cancer Center in Houston, Texas, commented that the results were "amazing" and that the vaccine "starts programming a response to kill the cancer".

Statistics:

  • The study analyzed medical records of over 1,000 individuals suffering from lung cancer or melanoma.
  • The survival benefit for vaccinated patients was found to be up to 37 months, a near doubling of the 21-month survival time for unvaccinated patients.
  • The study found that patients with metastatic melanoma survived an average of 27 months, while vaccinated patients survived so long that the researchers couldn't calculate an average survival time.

Sources:

  • Nature (journal)
  • Express (news outlet)
  • Lu ShaoJi (Getty Images)
  • Adam Grippin, a radiation oncologist at MD Anderson Cancer Center in Houston, Texas
  • Benoit Van den Eynde, a tumour immunologist at the University of Oxford
  • "mRNA Covid vaccine extends survival in patients with specific cancer" (Nature article)